Pfizer disclosed positive mid-stage data for PF-08653944 (Metsera origin) showing clinically meaningful, once-monthly weight loss and tolerability, and announced plans for an extensive Phase 3 program. The company is moving to higher maintenance doses in pivotal studies and expects a broad, 10-study Phase 3 plan aimed at obesity indications after its $10 billion Metsera acquisition. Pfizer executives said the Phase 2 results increase confidence but acknowledged the company will test higher doses to better compete with established GLP-1 leaders. The readouts add pressure to the obesity field as incumbents and new entrants jockey on dose, schedule and durability of weight loss.